<p>DAVENPORT &amp; Co LLC 在第三季度购买了 Cognition Therapeutics, Inc. (NASDAQ:CGTX - 免费报告) 的新股份，根据其最近向 SEC 提交的文件。该基金购买了 2,689,336 股公司股票，价值约为 3,631,000 美元。截至其最近向 SEC 提交的文件，DAVENPORT &amp; Co LLC 拥有 Cognition Therapeutics 约 3.66% 的股份。</p>
<ul>
<li>11 月的小型股珍宝：3 只有望增长的股票</li>
</ul>
<p>另外，Northeast Financial Consultants Inc 在第一季度将其在 Cognition Therapeutics 的股份增加了 158.6%。Northeast Financial Consultants Inc 目前拥有 63,351 股公司股票，价值 27,000 美元，在此期间又购买了 38,851 股。当前 43.35% 的股票由机构投资者持有。</p>
<p>获取 <strong>Cognition Therapeutics</strong> 的提醒：</p>
<h2>Cognition Therapeutics 股价下跌 0.7%</h2>
<p>Cognition Therapeutics 股票周五开盘价为 1.45 美元。该公司的 50 日移动平均价格为 1.61 美元，200 日移动平均价格为 1.37 美元。Cognition Therapeutics, Inc. 的 12 个月低点为 0.22 美元，12 个月高点为 3.83 美元。该股票的市值为 1.2799 亿美元，市盈率为 -3.02，贝塔值为 1.23。</p>
<p>Cognition Therapeutics (NASDAQ:CGTX - 获取免费报告) 最近于 11 月 6 日发布了季度财报。该公司报告季度每股收益为（0.06）美元，超出分析师共识预期的（0.07）美元 0.01 美元。整体来看，卖方分析师预测 Cognition Therapeutics, Inc. 本年度将发布 -0.8 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票分析师最近对 CGTX 股票发表了评论。华尔街 Zen 在 11 月 8 日的研究报告中将 Cognition Therapeutics 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 12 月 4 日的报告中重申了 “买入” 评级，并对 Cognition Therapeutics 的股票设定了 3.00 美元的目标价。Weiss Ratings 在周一的研究报告中重申了对 Cognition Therapeutics 的 “卖出（d-）” 评级。最后，B. Riley 在 11 月 21 日的研究报告中重新发布了 “买入” 评级，并将 Cognition Therapeutics 的目标价从 2.00 美元上调至 3.00 美元。一位研究分析师对该股票给予了强烈买入评级，三位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 3.33 美元。</p>
<p><strong>获取我们关于 Cognition Therapeutics 的最新研究报告</strong></p>
<h2>Cognition Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Cognition Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发针对神经退行性疾病的疾病修正疗法，重点关注阿尔茨海默病。该公司的主要研究候选药物 CT1812 是一种口服小分子，能够拮抗 sigma-2 受体复合物，以保护突触免受淀粉样β寡聚体毒性的影响。通过针对一种新机制，Cognition Therapeutics 旨在减缓或逆转阿尔茨海默病患者的认知衰退。</p>
<p>CT1812 已成功完成第一阶段安全性研究和初步第二阶段临床试验，目前正在北美和欧洲对轻度至中度阿尔茨海默病患者进行多项第二阶段临床研究。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Cognition Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><strong>想看看其他对 CGTX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Cognition Therapeutics, Inc. (NASDAQ:CGTX - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cognition Therapeutics 吗？</h2>
<p>在考虑投资 Cognition Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Cognition Therapeutics 并不在名单上。</p>
<p>虽然 Cognition Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CGTX

<p>DAVENPORT & Co LLC 投资了 Cognition Therapeutics, Inc.，购买了 2,689,336 股，价值 3,631,000 美元，持有该公司 3.66% 的股份。Cognition Therapeutics 的股票开盘价为 1.45 美元，市值为 1.2799 亿美元。分析师的评级不一，普遍目标价为 3.33 美元。该公司专注于阿尔茨海默病疗法，其主要候选药物 CT1812 正在进行第二阶段临床试验</p>

<p>DAVENPORT &amp; Co LLC purchased a new stake in Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 2,689,336 shares of the company's stock, valued at approximately $3,631,000. DAVENPORT &amp; Co LLC owned about 3.66% of Cognition Therapeutics as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>DAVENPORT &amp; Co LLC 在第三季度购买了 Cognition Therapeutics, Inc. (NASDAQ:CGTX - 免费报告) 的新股份，根据其最近向 SEC 提交的文件。该基金购买了 2,689,336 股公司股票，价值约为 3,631,000 美元。截至其最近向 SEC 提交的文件，DAVENPORT &amp; Co LLC 拥有 Cognition Therapeutics 约 3.66% 的股份。</p>
</div><ul>
<li>November’s Small-Cap Treasures: 3 Stocks Poised for Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>11 月的小型股珍宝：3 只有望增长的股票</li>
</ul>
</div><p>Separately, Northeast Financial Consultants Inc grew its position in shares of Cognition Therapeutics by 158.6% in the first quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company's stock valued at $27,000 after purchasing an additional 38,851 shares during the period. 43.35% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>另外，Northeast Financial Consultants Inc 在第一季度将其在 Cognition Therapeutics 的股份增加了 158.6%。Northeast Financial Consultants Inc 目前拥有 63,351 股公司股票，价值 27,000 美元，在此期间又购买了 38,851 股。当前 43.35% 的股票由机构投资者持有。</p>
</div><p>Get <strong>Cognition Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cognition Therapeutics</strong> 的提醒：</p>
</div><h2>Cognition Therapeutics Trading Down 0.7%</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 股价下跌 0.7%</h2>
</div><p>Shares of Cognition Therapeutics stock opened at $1.45 on Friday. The business's fifty day moving average price is $1.61 and its 200 day moving average price is $1.37. Cognition Therapeutics, Inc. has a twelve month low of $0.22 and a twelve month high of $3.83. The stock has a market capitalization of $127.99 million, a P/E ratio of -3.02 and a beta of 1.23.</p>
<div class="lb-trans"><p>Cognition Therapeutics 股票周五开盘价为 1.45 美元。该公司的 50 日移动平均价格为 1.61 美元，200 日移动平均价格为 1.37 美元。Cognition Therapeutics, Inc. 的 12 个月低点为 0.22 美元，12 个月高点为 3.83 美元。该股票的市值为 1.2799 亿美元，市盈率为 -3.02，贝塔值为 1.23。</p>
</div><p>Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. As a group, sell-side analysts predict that Cognition Therapeutics, Inc. will post -0.8 EPS for the current year.</p>
<div class="lb-trans"><p>Cognition Therapeutics (NASDAQ:CGTX - 获取免费报告) 最近于 11 月 6 日发布了季度财报。该公司报告季度每股收益为（0.06）美元，超出分析师共识预期的（0.07）美元 0.01 美元。整体来看，卖方分析师预测 Cognition Therapeutics, Inc. 本年度将发布 -0.8 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities analysts recently commented on CGTX shares. Wall Street Zen upgraded Cognition Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th. HC Wainwright restated a &#34;buy&#34; rating and issued a $3.00 price target on shares of Cognition Therapeutics in a report on Thursday, December 4th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Cognition Therapeutics in a research note on Monday. Finally, B. Riley reissued a &#34;buy&#34; rating and issued a $3.00 target price (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $3.33.</p>
<div class="lb-trans"><p>几位股票分析师最近对 CGTX 股票发表了评论。华尔街 Zen 在 11 月 8 日的研究报告中将 Cognition Therapeutics 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 12 月 4 日的报告中重申了 “买入” 评级，并对 Cognition Therapeutics 的股票设定了 3.00 美元的目标价。Weiss Ratings 在周一的研究报告中重申了对 Cognition Therapeutics 的 “卖出（d-）” 评级。最后，B. Riley 在 11 月 21 日的研究报告中重新发布了 “买入” 评级，并将 Cognition Therapeutics 的目标价从 2.00 美元上调至 3.00 美元。一位研究分析师对该股票给予了强烈买入评级，三位给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 3.33 美元。</p>
</div><p><strong>Get Our Latest Research Report on Cognition Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Cognition Therapeutics 的最新研究报告</strong></p>
</div><h2>Cognition Therapeutics Profile</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer's disease. The company's lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer's disease.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发针对神经退行性疾病的疾病修正疗法，重点关注阿尔茨海默病。该公司的主要研究候选药物 CT1812 是一种口服小分子，能够拮抗 sigma-2 受体复合物，以保护突触免受淀粉样β寡聚体毒性的影响。通过针对一种新机制，Cognition Therapeutics 旨在减缓或逆转阿尔茨海默病患者的认知衰退。</p>
</div><p>CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer's disease.</p>
<div class="lb-trans"><p>CT1812 已成功完成第一阶段安全性研究和初步第二阶段临床试验，目前正在北美和欧洲对轻度至中度阿尔茨海默病患者进行多项第二阶段临床研究。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Cognition Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Cognition Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CGTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 CGTX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Cognition Therapeutics, Inc. (NASDAQ:CGTX - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CGTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cognition Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cognition Therapeutics 吗？</h2>
</div><p>Before you consider Cognition Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Cognition Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Cognition Therapeutics 并不在名单上。</p>
</div><p>While Cognition Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cognition Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

DAVENPORT & Co LLC 对 Cognition Therapeutics, Inc. $CGTX 进行了新的投资